Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in Adult XLH (BurGER)
NCT04695860Phase 3Completed
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of burosumab in X-linked hypophosphatemia (XLH). Started Jan 2021; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT04695860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695860.